2027 FEHB Program Changes

Next year, all FEHB plans will require members to undergo Intensive Behavioral Therapy (IBT) both before a GLP-1 is authorized and during treatment. IBT is only required for those receiving GLP-1s prescribed for weight loss. If you receive a GLP-1 to manage a chronic condition like Type 2 diabetes, you won’t be subject to the IBT requirement.
OPM has provided the following information: “Plans are expected to cover specified individual and group intensive behavioral therapy and medical nutrition therapy services, including between 12–22 intensive behavioral therapy sessions per year depending on progress.”
Besides stricter prior-authorization requirements, FEHB members will also face higher out-of-pocket costs for GLP-1s as most FEHB carriers have increased the member cost share for these drugs to 50%.
There are other ways of acquiring GLP-1s that FEHB members may want to consider.
- Active employees and annuitants without Part D, may want to consider pharmaceutical discount coupons. The prices could be lower and the prior authorization requirement is generally a prescription from your doctor which would likely not require Intensive Behavioral Therapy. Keep in mind that if you choose this route your out-of-pocket costs for your medication wouldn't count toward your FEHB deductible or catastrophic limit.
- Annuitants with Part D have two options:
- Part D may offer lower prices on GLP-1s compared to FEHB coverage. Use the prescription drug pricing tool from your carrier to see if there are savings from Part D.
- You may be able to use the GLP-1 Bridge Program if the GLP-1 you want is not covered by your plan. You will have to meet the Body Mass Index requirements to be eligible for the program. If approved you'll pay just $50/month for one of the three GLP-1s available in the Bridge Program: Foundayo, Wegovy, and Zepbound.
One other change for those enrolled in Part D, either from a Part D plan or for those enrolled in a Medicare Advantage plan that bundles Part, the catastrophic limit will rise from $2,100 this year to $2,400 next year for covered medications.